Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age more than or equal to 18 years at the time of signing informed consent~* Body mass index more than or equal to 30 kg/m\^2 or more than or equal to 27 kg/m\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Hemoglobin A1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening~* A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
- Semaglutide placebo (Type: PLACEBO_COMPARATOR): Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).